TP53 and neoplasm: In conclusion, the present study demonstrated that the combination of in situ gene therapy with rAd-p53 and immunotherapy with an anti-PD-1 antibody induced good anti-tumor activity in mouse TRAMP-C2 and Renca syngeneic tumor models, which both express CAR.